組蛋白去乙醯酶1 (EC 3.5.1.98) :開發中產品分析

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Drugs In Development, 2021

出版日期: 2021年08月31日 | 出版商:

Global Markets Direct | 英文 191 Pages | 訂單完成後即時交付

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全貌
簡介
目錄

簡介

本報告提供組蛋白去乙醯酶1 (EC 3.5.1.98)的開發情形調查分析，提供您開發中產品的概要，臨床實驗的各階段產品概要，主要企業簡介，藥物簡介，開發中產品的最新趨勢，最新消息和新聞稿等系統性資訊。

簡介

概要

治療藥的開發

開發中的產品:各開發階段
開發中的產品:各治療領域
開發中的產品:各適應症

開發中產品的概要

後期階段的產品
初期階段的產品

開發中的產品:各企業

開發中的產品:各大學/研究機關

治療藥的評估

單劑/聯合治療別
各作用機制
各給藥途徑
各分子類型

開發治療藥的企業

4SC AG
Acetylon Pharmaceuticals, Inc.
Chipscreen Biosciences Ltd
Curis, Inc.
GlaxoSmithKline Plc
HitGen LTD
IRBM Science Park SpA
Italfarmaco S.p.A.
MEI Pharma, Inc.
Merck & Co., Inc.
Mirati Therapeutics Inc.
Oncolys BioPharma Inc.
Sigma-Tau S.p.A.
Syndax Pharmaceuticals, Inc.
TetraLogic Pharmaceuticals

藥物簡介

暫停的計劃

附錄

Product Code: GMDHC2940TDB

Summary:

According to the recently published report 'Histone Deacetylase 1 - Drugs In Development, 2021'; Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) pipeline Target constitutes close to 39 molecules. Out of which approximately 31 molecules are developed by companies and remaining by the universities/institutes.

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Histone deacetylase 1 is an enzyme encoded by the HDAC1 gene. The protein encoded by this gene belongs to the histone deacetylase family and is a component of the histone deacetylase complex. It also interacts with retinoblastoma tumor-suppressor protein and this complex is a key element in the control of cell proliferation and differentiation. Together with metastasis-associated protein-2 MTA2, it deacetylates p53 and modulates its effect on cell growth and apoptosis. It plays an important role in transcriptional regulation, cell cycle progression and developmental events.

The report 'Histone Deacetylase 1 - Drugs In Development, 2021' outlays comprehensive information on the Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 7, 1, 17 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Hematological Disorders, Cardiovascular, Gastrointestinal, Immunology, Infectious Disease and Musculoskeletal Disorders which include indications Breast Cancer, Melanoma, Diffuse Large B-Cell Lymphoma, Non-Small Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Follicular Lymphoma, Colorectal Cancer, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Mycosis Fungoides, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Triple-Negative Breast Cancer (TNBC), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Cutaneous T-Cell Lymphoma, Essential Thrombocythemia, Glioblastoma Multiforme (GBM), HER2- Breast Cancer, Liver Cancer, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Melanoma, Myelodysplastic Syndrome, Pancreatic Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Small-Cell Lung Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Unspecified B-Cell Lymphomas, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Alzheimer's Disease, Anal Cancer, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), Basal Cell Carcinoma (Basal Cell Epithelioma), Becker Muscular Dystrophy, Beta Thalassaemia, Bladder Cancer, Blood Cancer, Bone Disorders, Cervical Cancer, Charcot-Marie-Tooth Disease Type II, Chronic Lymphocytic Leukemia (CLL), CNS Lymphoma, Cognitive Disorders, Colon Cancer, Duchenne Muscular Dystrophy, Gallbladder Cancer, Gastrointestinal Tract Cancer, Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hemoglobinopathies, High-Grade Glioma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Ischemia Reperfusion Injury, Kidney Cancer (Renal Cell Cancer), Liver Fibrosis, Lung Adenocarcinoma, Lung Cancer, Lymphoma, Merkel Cell Carcinoma, Metastatic Breast Cancer, Multiple Sclerosis, Myelofibrosis, Natural Killer Cell Lymphomas, Neuroblastoma, Non-Hodgkin Lymphoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Ovarian Cancer, Parkinson's Disease, Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Prostate Cancer, Rectal Cancer, Recurrent Medulloblastoma, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Rhabdomyosarcoma, Sezary Syndrome, Sickle Cell Disease, Skin Cancer, Solid Tumor, Squamous Cell Carcinoma, Systemic Lupus Erythematosus, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), T-Cell Lymphomas, Unspecified Cancer, Unspecified Central Nervous System Disorders, Ureter Cancer, Urethral Cancer and Vulvar Cancer.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)
The report reviews Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
The report assesses Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics

Reasons to Buy:

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) development landscape
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Introduction
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Overview
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Therapeutics Development
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Therapeutics Assessment
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Drug Profiles
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Dormant Products
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Discontinued Products
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Product Development Milestones
Appendix